A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy

Video

In the first installment of this series, Joshua Sabari, MD, provides an overview on the use of chemotherapy for first-line treatment of NSCLC, and discusses how the more recent availability of PD-1/PD-L1– and CTLA-4–targeted immunotherapy is changing the field.

Related Videos
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Video 6 - "Current Approaches to Treatment Sequencing in HER2+ Breast Cancer"
Video 5 - "Exciting Developments in HER2+ Breast Cancer"
Video 4 - "KATHERINE: Adjuvant T-DM1 vs Trastuzumab for Residual Invasive HER2+ Breast Cancer"
Video 3 - "APHINITY Trial: Pertuzumab for Patients with HER2+ Breast Cancer"
Rebecca A. Shatsky, MD, an expert on breast cancer